Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1980 May 1;151(5):1275–1287. doi: 10.1084/jem.151.5.1275

The role of specific antibody in alternative complement pathway- mediated opsonophagocytosis of type III, group B Streptococcus

PMCID: PMC2185859  PMID: 6989947

Abstract

The native capsular polysaccharide antigen of type III, group B Streptococcus contains a terminal sialic acid residue on each repeating unit that masks all end-group galactopyranose residues and prevents alternative pathway complement activation by adult human sera in the absence of type-specific antibody. The critical role of the sialic acid residues in allowing the organism to evade activating the alternative complement pathway was shown when neuraminidase treatment of the organism converted the bacteria to activators of the alternative pathway as assessed in agammaglobulinemic serum. The requirement for specific antibody in permitting alternative pathway activation by the fully sialated bacteria was shown when sera that contained low levels of specific antibody failed to activate this pathway, and when prior absorption of serum that contained higher type-specific antibody levels with the capsular antigen failed to activate this pathway. The use of C2-deficient sera showed that the calssical pathway was not required for antibody-dependent alternative pathway activation. The use of isotonic, pH 7.5, veronal-NaCl buffer that contained 1% gelatin and that was supplemented to 4 mM Mg++ and 16 mM EGTA and adjusted to pH 7.5 (MgEGTA) ruled out the participation of the C1-bypass pathway. The presence of sialic acid on the bacterial surface is one means of evading an important mechanism of natural immunity, namely activation of complement by the alternative pathway. Only specific antibody, i.e., acquired immunity, can overcome this virulence factor.

Full Text

The Full Text of this article is available as a PDF (820.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper C. A., Rosen F. S., Lachmann P. J. Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A. 1972 Oct;69(10):2910–2913. doi: 10.1073/pnas.69.10.2910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baker C. J., Kasper D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976 Apr 1;294(14):753–756. doi: 10.1056/NEJM197604012941404. [DOI] [PubMed] [Google Scholar]
  3. Baker C. J., Kasper D. L., Davis C. E. Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus. J Exp Med. 1976 Feb 1;143(2):258–270. doi: 10.1084/jem.143.2.258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baker C. J., Kasper D. L. Microcapsule of type III strains of group B Streptococcus: production and morphology. Infect Immun. 1976 Jan;13(1):189–194. doi: 10.1128/iai.13.1.189-194.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baker C. J., Kasper D. L., Tager IRAB, Paredes A., Alpert S., McCormack W. M., Goroff D. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest. 1977 May;59(5):810–818. doi: 10.1172/JCI108703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Baker P. J., Stashak P. W., Prescott B. Use of erythrocytes sensitized with purified pneumococcal polysaccharides for the assay of antibody and antibody-producing cells. Appl Microbiol. 1969 Mar;17(3):422–426. doi: 10.1128/am.17.3.422-426.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Baltimore R. S., Kasper D. L., Baker C. J., Goroff D. K. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol. 1977 Feb;118(2):673–678. [PubMed] [Google Scholar]
  8. Bjornson A. B., Bjornson H. S. Participation of immunoglobulin and the alternative complement pathway in opsonization of Bacteroides fragilis and Bacteroides thetaiotaomicron. J Infect Dis. 1978 Sep;138(3):351–358. doi: 10.1093/infdis/138.3.351. [DOI] [PubMed] [Google Scholar]
  9. Bjornson A. B., Michael J. G. Factors in human serum promoting phagocytosis of Pseudomonas aeruginosa. I. Interaction of opsonins with the bacterium. J Infect Dis. 1974 Nov;130 (Suppl)(0):S119–S126. doi: 10.1093/infdis/130.supplement.s119. [DOI] [PubMed] [Google Scholar]
  10. Brade V., Dieminger L., Schmidt G., Vogt W. Incompatibility between C3b and B of guinea-pig and man and its influence on the titration of the alternative pathway factors D and B in these two species. Immunology. 1976 Feb;30(2):171–179. [PMC free article] [PubMed] [Google Scholar]
  11. Czop J. K., Fearon D. T., Austen K. F. Membrane sialic acid on target particles modulates their phagocytosis by a trypsin-sensitive mechanism on human monocytes. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3831–3835. doi: 10.1073/pnas.75.8.3831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Czop J. K., Fearon D. T., Austen K. F. Opsonin-independent phagocytosis of activators of the alternative complement pathway by human monocytes. J Immunol. 1978 Apr;120(4):1132–1138. [PubMed] [Google Scholar]
  13. Edwards M. S., Baker C. J., Kasper D. L. Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. J Infect Dis. 1979 Dec;140(6):1004–1008. doi: 10.1093/infdis/140.6.1004. [DOI] [PubMed] [Google Scholar]
  14. Fearon D. T., Austen K. F. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683–1687. doi: 10.1073/pnas.74.4.1683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fearon D. T., Austen K. F. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med. 1977 Jul 1;146(1):22–33. doi: 10.1084/jem.146.1.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fearon D. T. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971–1975. doi: 10.1073/pnas.75.4.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gigli I., Nelson R. A., Jr Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. Exp Cell Res. 1968 Jul;51(1):45–67. doi: 10.1016/0014-4827(68)90158-4. [DOI] [PubMed] [Google Scholar]
  18. Hemming V. G., Hall R. T., Rhodes P. G., Shigeoka A. O., Hill H. R. Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence. J Clin Invest. 1976 Dec;58(6):1379–1387. doi: 10.1172/JCI108593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hill H. R., Shigeoka A. O., Hall R. T., Hemming V. G. Neonatal cellular and humoral immunity to group B streptococci. Pediatrics. 1979 Nov;64(5 Pt 2 Suppl):787–794. [PubMed] [Google Scholar]
  20. Jennings H. J., Rosell K. G., Kasper D. L. Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus. Can J Biochem. 1980 Feb;58(2):112–120. doi: 10.1139/o80-016. [DOI] [PubMed] [Google Scholar]
  21. Kasper D. L., Baker C. J., Baltimore R. S., Crabb J. H., Schiffman G., Jennings H. J. Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med. 1979 Feb 1;149(2):327–339. doi: 10.1084/jem.149.2.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kazatchkine M. D., Fearon D. T., Austen K. F. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol. 1979 Jan;122(1):75–81. [PubMed] [Google Scholar]
  23. May J. E., Frank M. M. Hemolysis of sheep erythrocytes in guinea pig serum deficient in the fourth component of complement. II. Evidence for involvement of C1 and components of the alternate complement pathway. J Immunol. 1973 Dec;111(6):1668–1676. [PubMed] [Google Scholar]
  24. Mayer M. M. Complement, past and present. Harvey Lect. 1978;72:139–193. [PubMed] [Google Scholar]
  25. McCARTY M., LANCEFIELD R. C. Variation in the group-specific carbohydrate of group A streptococci. I. Immunochemical studies on the carbohydrates of variant strains. J Exp Med. 1955 Jul 1;102(1):11–28. doi: 10.1084/jem.102.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Müller-Eberhard H. J., Götze O. C3 proactivator convertase and its mode of action. J Exp Med. 1972 Apr 1;135(4):1003–1008. doi: 10.1084/jem.135.4.1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Nelson B., Ruddy S. Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement. J Immunol. 1979 May;122(5):1994–1999. [PubMed] [Google Scholar]
  28. Nicholson A., Brade V., Lee G. D., Shin H. S., Mayer M. M. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly. J Immunol. 1974 Mar;112(3):1115–1123. [PubMed] [Google Scholar]
  29. Nydegger U. E., Fearon D. T., Austen K. F. The modulation of the alternative pathway of complement in C2-deficient human serum by changes in concentration of the component and control proteins. J Immunol. 1978 Apr;120(4):1404–1408. [PubMed] [Google Scholar]
  30. Pangburn M. K., Müller-Eberhard H. J. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A. 1978 May;75(5):2416–2420. doi: 10.1073/pnas.75.5.2416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Polhill R. B., Jr, Newman S. L., Pruitt K. M., Johnston R. B., Jr Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation. J Immunol. 1978 Jul;121(1):371–376. [PubMed] [Google Scholar]
  32. Reed W. P., Albright E. L. Serum factors responsible for killing of Shigella. Immunology. 1974 Jan;26(1):205–215. [PMC free article] [PubMed] [Google Scholar]
  33. Robbins J. B., McCracken G. H., Jr, Gotschlich E. C., Orskov F., Orskov I., Hanson L. A. Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med. 1974 May 30;290(22):1216–1220. doi: 10.1056/NEJM197405302902202. [DOI] [PubMed] [Google Scholar]
  34. Root R. K., Ellman L., Frank M. M. Bactericidal and opsonic properties of C4-deficient guinea pig serum. J Immunol. 1972 Sep;109(3):477–486. [PubMed] [Google Scholar]
  35. Schreiber R. D., Pangburn M. K., Lesavre P. H., Müller-Eberhard H. J. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3948–3952. doi: 10.1073/pnas.75.8.3948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Shigeoka A. O., Hall R. T., Hemming V. G., Allred C. D., Hill H. R. Role of antibody and complement in opsonization of group B streptococci. Infect Immun. 1978 Jul;21(1):34–40. doi: 10.1128/iai.21.1.34-40.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Verhoef J., Peterson P., Kim Y., Sabath L. D., Quie P. G. Opsonic requirements for staphylococcal phagocytosis. Heterogeneity among strains. Immunology. 1977 Aug;33(2):191–197. [PMC free article] [PubMed] [Google Scholar]
  38. Weiler J. M., Daha M. R., Austen K. F., Fearon D. T. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268–3272. doi: 10.1073/pnas.73.9.3268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Whaley K., Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med. 1976 Nov 2;144(5):1147–1163. doi: 10.1084/jem.144.5.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Winkelstein J. A., Shin H. S. The role of immunoglobulin in the interaction of pneumococci and the properdin pathway: evidence for its specificity and lack of requirement for the Fc portion of the molecule. J Immunol. 1974 May;112(5):1635–1642. [PubMed] [Google Scholar]
  41. Winkelstein J. A., Shin H. S., Wood W. B., Jr Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation. J Immunol. 1972 Jun;108(6):1681–1689. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES